Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KLA Corp. (KLAC) vs Revvity Inc (RVTY) Price & Performance

Revvity IncTrade

Price performance (Past 24H)

Key statistics

KLA Corp. vs Revvity Inc — how do they compare? KLA Corp. trades at $207.68 (market cap $261.92B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: KLA Corp. is far larger — about 20.3× Revvity Inc's market cap, and KLA Corp. pays the higher dividend (0.46%). Which is the better fit depends on your goals.

KLACRVTY
Market Cap
$261.92B$12.91B
Sector
TechnologyTechnology
52-Week High
$301.71$117.75
52-Week Low
$84.39$82.26
Enterprise Value
$263.17B$15.23B
Dividend Yield
0.46%0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KLA Corp.

KLA Corporation (KLAC) trades at $208.27, up 8.06% on the day, reflecting strong momentum amid the AI-driven semiconductor equipment rally. The stock exhibits bullish technical signals with recent earnings beats and robust profitability, including a 35.57% net income margin. Recent corporate actions include a 1:10 stock split and dividend declarations, while analyst consensus leans heavily bullish with a $246.93 price target.

Outlook remains positive given KLAC's exposure to advanced packaging growth and AI chip demand, though elevated valuation ratios (P/E of 54.77) and technical overbought conditions near resistance at $209 pose near-term risks. Long-term investors may find value in its fundamental strength, but volatility from sector cyclicality warrants caution.

Revvity Inc

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About KLA Corp.

KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.

Read more on KLAC

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY